133485-75-3

Upstream product

• 917-54-4 methyllithium 
• 133485-56-0 2-n-butyl-1-(2-chlorophenyl)methyl-1H-imidazole-5-carboxaldehyde 
• 17849-38-6 2-Chlorobenzyl alcohol 
• 68283-19-2 2-n-butyl-4-(hydroxymethyl)imidazole 
• 133486-41-6 1-acetyl-4-acetoxymethyl-2-n-butylimidazole 
• 133485-55-9 2-n-butyl-1-(2-chlorophenyl)-methyl-5-hydroxymethyl-1H-imidazole 
• 133486-42-7 2-n-butyl-5-(acetoxymethyl)-1-<(2-chlorophenyl)methyl>imidazole 

Downstream Products

• 1028289-77-1 methyl (E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-3-methyl-2-propenoate 
• 134405-47-3 (E)-3-<2-butyl-1-<(2-chlorophenyl)methyl>imidazol-5-yl>-2-butenoic acid 
• 135126-63-5 (E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(thien-3-yl)methyl-2-butenoic acid 
• 135123-72-7 methyl (E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(thien-3-yl)methyl-2-butenoate 
• 133485-76-4 2-butyl-1-<(2-chlorophenyl)methyl>5-acetylimidazole 

Relevant academic research and scientific papers

Substituted [1H-imidazol-5-ylialkanoic acids having angiotension II receptor antagonist activity

Angiotensin II receptor antagonists having the formula: STR1 which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

SUBSTITUTED IMIDAZOLES HAVING ANGIOTENSIN II RECEPTOR BLOCKING ACTIVITY

Angiotensin II receptor antagonists having the formula: STR1 which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of

Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists

Angiotensin II receptor antagonists having the formula: STR1 which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods of use thereof

Angiotensin II receptor antagonists having the formula: STR1 which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of

Imidazole-5-acrylic Acids: Potent Nonpeptide Angiotensin II Receptor Antagonists Designed Using a Novel Peptide Pharmacophore Model

A series a novel nonpeptide angiotensin II receptor antagonists containing a substituted (E)-acrylic acid has been developed.The overlay of 1, an imidazole-5-acetic acid found in the patent literature, on a novel pharmacophore model of AII suggested that extension of the acid side chain and attachment of a second aryl residue to mimic the C-terminal phenylalanine region of AII would lead to increased activity.A study of extended acid side chains at C-5 of the imidazole nucleus led to the discovery of the (E)-acrylic acid 5 as a promising starting point for further exploration.As predicted by the modeling, substitution of a benzyl group on the acrylic acid side chain to mimic the phenylalanine gave increased potency.An extensive study of the SAR of the newly introduced aromatic ring revealed that electron-rich heteroaryl rings provided improved activity, most notably in the in vivo rat models.Compound 40, (E)-3-imidazol-5-yl>-2--2-propenoic acid, has been shown to be a potent, competitive, and orally active small molecule AT-1 receptor antagonist.It exhibits a 2 orders of magnitude increase in binding affinity and a 10-fold improvement in in vivo potency as compared to compound 1 and represents an important milestone in the development of even more potent nonpeptide angiotensin II receptor antagonists.